Nautilus Biotechnology(US:NAUT)2025-10-27 21:48Financial Performance - Operating expenses for Q3 2025 were $15.5 million, a 19% decrease from $19.1 million in Q3 2024[4] - Net loss for Q3 2025 was $13.6 million, compared to a net loss of $16.4 million in the same period last year[4] - The company reported a net loss per share of $0.11 for Q3 2025, compared to $0.13 for Q3 2024[13] Assets and Liabilities - Cash, cash equivalents, and investments totaled $168.5 million as of September 30, 2025[5] - Total current assets increased to $134.3 million as of September 30, 2025, compared to $132.8 million at the end of 2024[12] - Total liabilities decreased to $31.8 million as of September 30, 2025, from $34.0 million at the end of 2024[12] - Total stockholders' equity decreased to $169.1 million as of September 30, 2025, from $208.7 million at the end of 2024[12] Research and Development - Research and development expenses for Q3 2025 were $9.6 million, down from $12.3 million in Q3 2024[13] - The company plans to launch an early access program for Tau proteoforms in the first half of 2026[8] - The company expects to share data on Tau proteoform samples at the upcoming World HUPO conference[8]